GE Healthcare’s cardiac spectral CT has received FDA 510(k) clearance, the company announced.
GE Healthcare’s cardiac spectral CT has received FDA 510(k) clearance, the company announced. The Discovery CT750 HD Freedom Edition addresses challenges in cardiac imaging such as coronary motion, calcium booming, plaque composition and accurate myocardial perfusion, the company said.
The system provides the following features: Motion Freedom with motion correction via SnapShot Freeze, which helps reduce cardiac motion by detecting vessel motion and velocity to determine the position and correct the effects of motion; Calcium Freedom with enhanced coronary visualization using Gemstone Spectra Imaging Cardiac; and Horizon Free, which provides plaque material composition assessment and accurate perfusion calculations.
The HD Freedom Edition’s first U.S. installation was at the University of Washington, Seattle, and is available in about two dozen locations in Europe and Japan, where physicians are using SnapShot Freeze and GSI Cardiac in routine practice for coronary evaluation.
According to GE, the system leads the industry in cardiac CT spatial resolution at 18.2 lp/cm, which helps physicians accurately quantify stenoses in coronary vessels by displaying reduction in calcium blooming compared to standard resolution.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.